The involvement of lipids in alzheimer's disease

Author Identifier

Ian James Martins

https://orcid.org/0000-0002-2390-1501

Ralph Martins

https://orcid.org/0000-0002-4828-9363

Document Type

Journal Article

Publisher

Elsevier

Faculty

Faculty of Health, Engineering and Science

School

School of Medical Sciences

RAS ID

17651

Funders

National Health and Medical Research Council

Grant Number

NHMRC Number: 1009295

Comments

Lim W.L.F., Martins I.J., & Martins R.N. (2014). The involvement of lipids in alzheimer's disease. Journal of Genetics and Genomics, 41(5), 261-274. Available here

Abstract

It has been estimated that Alzheimer's disease (AD), the most common form of dementia, will affect approximately 81 million individuals by 2040. To date, the actual cause and cascade of events in the progression of this disease have not been fully determined. Furthermore, there is currently no definitive blood test or simple diagnostic method for AD. Considerable efforts have been put into proteomic approaches to develop a diagnostic blood test, but to date these efforts have not been successful. More recently, there has been a stronger focus on lipidomic studies in the hope of increasing our understanding of the underlying mechanisms leading to AD and developing an AD blood test. It is well known that the strongest genetic risk factor for AD is the ε4 variant of apolipoprotein E (APOE). Evidence suggests that the ApoE protein, a major lipid transporter, plays a key role in the pathogenesis of AD, and its role in both normal and aberrant lipid metabolism warrants further extensive investigation. Here, we review ApoE-lipid interactions, as well as the roles that lipids may play in the pathogenesis of AD.

DOI

10.1016/j.jgg.2014.04.003

Access Rights

subscription content

Share

 
COinS